Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Phase I Clinical Trial to Test Combination of Two HIV Vaccine Candidates Starts in London

28.11.2008
The International AIDS Vaccine Initiative (IAVI) and the St. Stephen’s AIDS Trust at the Chelsea and Westminster Hospital have initiated a Phase I clinical trial in London, UK to test a prime-boost combination of two HIV vaccine candidates.

“Prevention is crucial in the fight against HIV and AIDS, and a vaccine is one of the most powerful prevention tools we know to combat infectious diseases,” said Professor Brian Gazzard, Research Director at the St. Stephen’s AIDS Trust and the principle investigator of this trial. “We hope this trial will contribute to a better understanding of how to induce with a vaccine an immune response to protect against HIV infection and AIDS.”

The news follows promising results recently announced by IAVI and partners for one of the two vaccine candidates to be tested, the MVA-based TBC-M4, which in a recent phase I trial generated modest immune responses in all volunteers who received the highest dose. According to Patricia Fast, Chief Medical Officer at the International AIDS Vaccine Initiative, “The responses observed with this vaccine candidate warrant further research to improve immune activation. We have learned from other studies that a prime-boost regimen has the potential to achieve just this.”

That is why the new trial will include a DNA-based vaccine candidate called ADVAX to prime the immune system. Previous Phase I studies with different DNA and MVA-based HIV vaccines in combination have shown that this prime-boost regimen was safe and well tolerated, and also able to generate enhanced immune responses when compared with the responses generated by either vaccine alone. The ADVAX vaccine candidate also offers economic value; it is relatively easy and cheap to manufacture, which makes it particularly appealing for use in the developing world.

A separate Phase I trial testing ADVAX and the MVA-based candidates in a prime-boost regime is planned for India. This trial would use a different mode of administration for the priming vaccine, different dosages and different vaccine regimens. Collectively, the results of both trials will help determine whether further development of both AIDS vaccine candidates in a prime-boost combination is warranted.

Deborah Jack, Chief Executive of the National AIDS Trust, comments: “The UK has always been a leader in the quest for new technologies to prevent HIV. Hosting a vaccine trial in London is a great opportunity to continue doing our part in the global fight against HIV and AIDS. Like any medical development, discovering an HIV vaccine is a naturally long process but when a vaccine is found it could save millions of lives globally, not just in the developing world but also in the UK.”

About the vaccine candidates
The vaccine candidate TBC-M4 is based on a vector built from recombinant Modified Vaccinia Ankara (MVA). It was designed by a biotech firm in the U.S. in collaboration with Dr. Sekhar Chakrabarty from the National Institute of Cholera and Enteric Diseases (NICED) in Kolkata, India . It targets HIV-1 subtype C, the most predominant HIV subtype in India, and contains 6 HIV genes : env, gag, reverse transcriptase, rev, tat and nef.

The vaccine candidate ADVAX is a plasmid DNA vaccine containing HIV-1 subtype C genes env, gag, pol, nef and tat. The vaccine was designed by the Aaron Diamond Research Centre in New York, through collaboration with Rockefeller University in New York and the International AIDS Vaccine Initiative.

It should be noted that since both vaccine candidates contain only synthetic copies of part of HIV’s genetic material, they cannot cause HIV infection.

ADVAX will be administered with a needle-free device (Biojector 2000), and the trial will also assess whether this delivery mechanism provides benefits over regular injection with a needle and syringe. ”Needle-free injection of a DNA vaccine can provide enhanced immune responses compared with administration by needle and syringe,” according to Dr. Richard Stout, Executive Vice President and Chief Medical Officer of Bioject Medical Technologies Inc., manufacturer of the device.

About the trial
The trial is a Phase I randomized, double-blind, placebo-controlled trial. It evaluates the safety and immunogenicity of ADVAX and TBC-M4 vaccines in a prime-boost regimen. The trial is recruiting 32 volunteers who are healthy HIV-negative men and women at low risk for HIV infection. All volunteers must provide full informed consent for their participation in the trial.

In addition to using standard immunology assays to measure the responses following vaccination, the trial will also evaluate a novel viral suppression assay. This assay provides a functional assessment of the immune response by measuring anti-viral activity. “There are indications from previous clinical studies that the laboratory assays currently used in HIV vaccine clinical trials are not an accurate predictor of whether a vaccine can prevent or control HIV infection,” said Dr. Jill Gilmour, Senior Director of Clinical Research at IAVI. “We urgently need to identify which laboratory tests give us insight into whether a person will resist infection with HIV or development of AIDS. This will enable researchers to select the most promising vaccine candidates for large-scale efficacy testing.”

It is expected that the trial will take 14 months to complete. The trial is fully sponsored by the International AIDS Vaccine Initiative.

Hester Kuipers | alfa
Further information:
http://www.iavi.org

Further reports about: ADVAX Aids DNA HIV HIV infection HIV vaccine HIV-1 IAVI MVA-based Phase I Clinical Trial TBC-M4 Vaccine combination immune response

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

NASA's Fermi catches gamma-ray flashes from tropical storms

25.04.2017 | Physics and Astronomy

Researchers invent process to make sustainable rubber, plastics

25.04.2017 | Materials Sciences

Transfecting cells gently – the LZH presents a GNOME prototype at the Labvolution 2017

25.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>